Recovery of ovarian function by human embryonic stem cell-derived mesenchymal stem cells in cisplatin-induced premature ovarian failure in mice
Authors:
Open Access
- 26 June 2020
- journal article
- research article
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 11 (1) , 1-13
Abstract
Background: Clinical use of mesenchymal stem cells (MSCs) requires a uniform cell population, and their harvesting is invasive and produces a limited number of cells. Human embryonic stem cell-derived MSCs (hESC-MSCs) can differentiate into three germ layers and possess immunosuppressive effects in vitro. Anticancer treatment is a well-known risk factor for premature ovarian failure (POF). In this study, we investigated the effect of hESC-MSC on recovery of ovarian function in cisplatin-induced POF in mice. Methods: Female mice received intraperitoneal cisplatin for 10 days. On day 12, CHA15-derived hESC-MSCs were transplanted into the mice by tail vein injection. An injection of PBS served as the negative control. Ovaries were removed 28 days after transplantation for assessment of ovarian histology, immunostaining, and fertility testing by superovulation and in vitro fertilization. hESC-MSC transplantation into mice with cisplatin-induced damage restored body weight and ovary size. Results: Mean primary and primordial follicle counts in the hESC-MSC group were significantly improved compared to the PBS group (P < 0.05), and counts of zona pellucida remnants, an apoptotic sign in ovarian follicles, were significantly reduced (P < 0.05). TUNEL assays and cleaved PARP immunostaining indicated apoptosis, which led to loss of ovarian stromal cells in negative control mice, while Ki-67 was higher in the hESC-MSC group and in non-cisplatin-treated controls than in the PBS group. Ovulation was reduced in the PBS group but recovered significantly in the hESC-MSC group. Rates of blastocyst formation from ovulated eggs and live births per mouse also recovered significantly in the hESC-MSC group. Conclusions: hESC-MSC restored structure and function in the cisplatin-damaged ovary. Our study provides new insights into the great clinical potential of human hESC-MSC in treating POF.Keywords
Funding Information
- Ministry of Education (NRF-2017R1D1A1B03028155.)
- Technology Innovation Program (Industrial Strategic Technology Development Program (MOTIE-20003838)
This publication has 34 references indexed in Scilit:
- Mesenchymal Stromal Cell-Seeded Biomimetic Scaffolds as a Factory of Soluble RANKL in Rankl-Deficient OsteopetrosisStem Cells Translational Medicine, 2018
- Exosomes derived from human adipose mesenchymal stem cells improve ovary function of premature ovarian insufficiency by targeting SMADStem Cell Research & Therapy, 2018
- Ethical and Safety Issues of Stem Cell-Based TherapyInternational Journal of Medical Sciences, 2018
- Human Embryonic Stem Cell Derived-Mesenchymal Stem Cells: An Alternative Mesenchymal Stem Cell Source for Regenerative Medicine TherapyRegenerative Medicine, 2014
- Chronic Inflammation (Inflammaging) and Its Potential Contribution to Age-Associated DiseasesThe Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 2014
- Mechanistic action of mesenchymal stem cell injection in the treatment of chemically induced ovarian failure in rabbitsCytotherapy, 2013
- Donor age and long-term culture affect differentiation and proliferation of human bone marrow mesenchymal stem cellsAnnals of Hematology, 2012
- Methods for quantifying follicular numbers within the mouse ovaryReproduction, 2004
- Long-term survivors of ovarian malignancies after cisplatin-based chemotherapyEuropean Journal of Cancer, 2004
- Early menopause in long-term survivors of cancer during adolescenceAmerican Journal of Obstetrics and Gynecology, 1992